Home > Dermatology > AAD 2019 > Late-Breakers > Novel anti-IgE drug enables durable urticaria control

Novel anti-IgE drug enables durable urticaria control

Presented By
Dr Diane Baker, Baker Allergy, Asthma, and Dermatology Clinic, USA
Conference
AAD 2019

In a previous phase 2b study (NCT02477332), the anti-IgE drug ligelizumab achieved greater control of symptoms compared with omalizumab and placebo in patients with chronic spontaneous urticaria (CSU) inadequately controlled with standard of care including H1-antihistamines for up to week 20 (last treatment at week 16). The results of an open-label 1-year extension study were presented, and more than 50% of CSU patients treated with ligelizumab had complete symptom control [1].

As much as 70.6% (226/320) of patients entered the extension study, with 88.9% (201/226) completing 1 year of treatment. Efficacy of therapy was assessed on the 7-day urticaria activity score (UAS7). During the first 12 weeks of the extension study, 52.2% of patients treated with ligelizumab attained a complete symptom control (UAS=0). “Complete responses were sustained and over half of the patients achieved UAS=0 at the end of week 52,” said Dr Diane Baker (Baker Allergy, Asthma, a...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on